Keros Therapeutics Files 8-K
Ticker: KROS · Form: 8-K · Filed: Jan 15, 2025 · CIK: 1664710
| Field | Detail |
|---|---|
| Company | Keros Therapeutics, Inc. (KROS) |
| Form Type | 8-K |
| Filed Date | Jan 15, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-filing, 8-K
TL;DR
Keros Therapeutics filed a routine 8-K on Jan 15, 2025. No major news.
AI Summary
Keros Therapeutics, Inc. filed an 8-K on January 15, 2025, reporting other events and financial statements. The filing does not contain specific details on new events, agreements, or financial figures beyond the standard reporting requirements.
Why It Matters
This 8-K filing indicates Keros Therapeutics is meeting its regulatory reporting obligations. Investors should review the full filing for any material updates not summarized here.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for reporting purposes and does not appear to contain any new material information that would immediately impact the company's risk profile.
Key Players & Entities
- Keros Therapeutics, Inc. (company) — Registrant
- January 15, 2025 (date) — Date of earliest event reported
- 001-39264 (other) — SEC File Number
- 811173868 (other) — IRS Employer Identification No.
- Lexington, Massachusetts (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing by Keros Therapeutics?
The primary purpose of this 8-K filing is to report "Other Events" and "Financial Statements and Exhibits" as of January 15, 2025.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is January 15, 2025.
What is Keros Therapeutics, Inc.'s SEC file number?
Keros Therapeutics, Inc.'s SEC file number is 001-39264.
Where are Keros Therapeutics, Inc.'s principal executive offices located?
Keros Therapeutics, Inc.'s principal executive offices are located at 1050 Waltham Street, Suite 302, Lexington, Massachusetts 02421.
Does this 8-K filing disclose any specific new material events or agreements?
Based on the provided text, this 8-K filing is a standard report and does not explicitly detail any specific new material events or agreements beyond the general categories of 'Other Events' and 'Financial Statements and Exhibits'.
Filing Stats: 479 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2025-01-15 06:31:23
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share KROS The Nasdaq Sto
Filing Documents
- kros-20250115.htm (8-K) — 36KB
- exhibit99111525pr.htm (EX-99.1) — 9KB
- 0001664710-25-000005.txt ( ) — 173KB
- kros-20250115.xsd (EX-101.SCH) — 2KB
- kros-20250115_lab.xml (EX-101.LAB) — 22KB
- kros-20250115_pre.xml (EX-101.PRE) — 13KB
- kros-20250115_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On January 15, 2025, Keros Therapeutics, Inc. announced that it has voluntarily halted all dosing in the TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension, including the 1.5 mg/kg and placebo treatment arms, based on the ongoing safety review due to new observations of pericardial effusion adverse events. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release dated January 15 , 202 5 . 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KEROS THERAPEUTICS, INC. By: /s/ Jasbir Seehra Jasbir Seehra, Ph.D. Chief Executive Officer Dated: January 15, 2025